

ESMO VIRTUAL CONGRESS 2020 INDUSTRY SATELLITE SYMPOSIUM

# Pushing the Boundaries

Expanding Treatment Options for Patients With Melanoma

NOVARTIS ONCOLOGY-SPONSORED

Available on-demand beginning

**Tuesday, 22 September 2020, 09:00 CEST**

Live Q&A and Discussion

**Wednesday, 23 September 2020, 11:00 - 11:30 CEST**

Dear Colleague,

I would like to invite you to attend a virtual symposium entitled *Pushing the Boundaries: Expanding Treatment Options for Patients with Melanoma* at the ESMO Virtual Congress 2020.

Significant advancements in the treatment of melanoma have been made following the introduction of targeted therapies and immune checkpoint inhibitors over a decade ago. These advancements have led to improvements in long-term outcomes that are now evident as key trials in both the adjuvant and metastatic setting have reported data with over 5 years of follow-up. The recent results provide insights into the benefits these treatments provide as well as highlighting the remaining unmet clinical need, thus demonstrating the opportunities where we can continue to push boundaries and further improve outcomes for our patients.

New clinical milestones are being achieved in the adjuvant melanoma treatment setting, as shown by the latest clinical data demonstrating a sustained relapse-free survival for both BRAF plus MEK inhibitors and anti-PD-1 monoclonal antibodies. Our panel of experts will provide their insights into how these data are influencing treatment within a multidisciplinary treatment setting along with their recommendations on how to address current clinical challenges.

The faculty will also discuss recent efforts to further treatment options for metastatic melanoma, including the latest data for novel combinations and therapeutic approaches. These efforts to further push the boundaries in the metastatic setting seek to address the ongoing unmet needs including therapeutic resistance and improving upon the depth and duration of response.

During this symposium, attendees will be encouraged to interact with our panel of melanoma experts who will be able to answer your questions. We look forward to you joining us!

Best Regards,



## SPEAKERS



**Reinhard Dummer, MD**  
University Hospital Zürich  
Skin Cancer Center  
Zürich, Switzerland



**Caroline Robert, MD, PhD**  
Gustave Roussy and  
Paris-Sud-Paris-Saclay University  
Villejuif, France



**Dirk Schadendorf, MD, PhD**  
Essen University Hospital  
Essen, Germany

## AGENDA

**Welcome From the Chair**  
Reinhard Dummer

**Achieving New Clinical Milestones in Adjuvant Melanoma**  
Caroline Robert with Clinical Insights from Reinhard Dummer

**State-of-the-Art and Emerging Treatment Options For Metastatic Melanoma**  
Dirk Schadendorf with Clinical Insights from Reinhard Dummer

**Closing Remarks**  
Reinhard Dummer



Novartis Pharma AG  
CH-4002 Basel Switzerland

This programme is supported by Novartis. This programme is intended for non-US physicians.

© 2020 Novartis

08/20

G-MTA-1233650